Dikhyaa Mohanty 
A rare neurological disorder called Guillain-Barre syndrome has been found in 11 individuals who had received the AstraZeneca-Oxford COVID-19 vaccine.
According to the two studies by clinicians in India and England, published in the Annals of Neurology, this unusual variant of the syndrome is characterised by prominent facial weakness. Seven such cases have been reported from a regional medical centre in Kerala, India, within two weeks of them being administrated the first dose of this vaccine, which is being produced and distributed in India as Covishield by Serum Institute of India (SII).
Similarly, four cases were reported from Nottingham, England, within three weeks of vaccination. According to an analysis of postvaccination events in Scotland, this vaccine slightly increases the risk of blood clotting and low platelets.
The UK’s Medicine and Healthcare products and Regulatory Agency have so far reported 379 cases of low platelet and blood clotting events.
